Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) EBIT (2020 - 2023)

Historic EBIT for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.0 million.

  • Terns Pharmaceuticals' EBIT fell 2488.71% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.0 million, marking a year-over-year decrease of 4512.08%. This contributed to the annual value of -$101.9 million for FY2024, which is 66.99% up from last year.
  • As of Q4 2023, Terns Pharmaceuticals' EBIT stood at -$21.0 million, which was down 2488.71% from -$29.7 million recorded in Q3 2023.
  • Over the past 5 years, Terns Pharmaceuticals' EBIT peaked at -$8.7 million during Q3 2020, and registered a low of -$29.7 million during Q3 2023.
  • For the 4-year period, Terns Pharmaceuticals' EBIT averaged around -$14.9 million, with its median value being -$13.9 million (2021).
  • As far as peak fluctuations go, Terns Pharmaceuticals' EBIT plummeted by 397.86% in 2022, and later plummeted by 7180.78% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' EBIT (Quarter) stood at -$8.8 million in 2020, then plummeted by 58.28% to -$13.9 million in 2021, then dropped by 21.26% to -$16.8 million in 2022, then dropped by 24.89% to -$21.0 million in 2023.
  • Its EBIT was -$21.0 million in Q4 2023, compared to -$29.7 million in Q3 2023 and -$17.8 million in Q2 2023.